1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024

The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024

  • August 2016
  • -
  • Persistence Market Research
  • -
  • 117 pages

Summary

Table of Contents

Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. The majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity. This study provides market analysis for various antibacterial drug classes used for the treatment of bacterial conjunctivitis. The stakeholders of this study comprise established pharmaceutical companies involved in the commercialization of antibacterial drugs as well as new participants who wish to enter the U.S. market.

This market study provides a complete analysis of the bacterial conjunctivitis drugs market in the U.S. and helps in identifying various market governing factors. The market overview section provides exhaustive information of the incidence rate of bacterial conjunctivitis, list of API manufacturers, patent challenges, market trends such as drivers, restraints, and growth opportunities that currently control the dynamics of the overall market. The section also recommends and predicts the future conditions of the market. Market strategy tools such as event impact assessment and Porter’s Five Forces analysis have also been incorporated in this report to provide balanced analysis about the level of competition within the bacterial conjunctivitis drugs market in the U.S. Executive summary provided in the report encapsulates comprehensive insights about every segment considered in this study. Besides, it includes a market snapshot, which offers a glimpse into the current scenario of the bacterial conjunctivitis drugs market in the U.S. in terms of current and future market size along cumulative growth rate. Additionally, this study includes a regulatory framework segment wherein the overall regulatory scenario of the U.S. drugs policy has been described. Participant analysis tools such as market share analysis have also been included in the market overview section of the report to deliver a broad spectrum of the overall market scenario in the bacterial conjunctivitis drugs market in the U.S.

The bacterial conjunctivitis drugs market in the U.S. has been segmented based on various antibacterial drug classes. The market is segmented into major types of antibacterial drugs such as fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones segment has been sub-segmented into ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and besifloxacin. Aminoglycosides have been sub-segmented into tobramycin and gentamycin. Macrolides has been divided into erythromycin and azithromycin. The others segment is analyzed cumulatively, considering bacitracin, fusidic acid, and ceftriaxone within this class. The market size for the period from 2012 to 2024 has been provided for each of the major drug classes mentioned above in terms of USD million. Along with the market size that were projected considering 2013 as the base year and 2012 as the historical year, the CAGR (%) of each market segment for the forecast period from 2012 to 2018 and 2018 to 2024 have also been provided.

The report concludes with detailed profiles of leading players in the bacterial conjunctivitis drugs (antibacterials) market in the U.S. The study profiles the companies in terms of overview, financial overview, product portfolio, business strategies, and recent developments. Major organizations profiled in this report include Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. Additionally, market share analysis that has been provided in context with the major pharmaceuticals operating in the market would help new participants to understand the key business perceptions and frameworks and to identify the specific product lines of the existing companies to establish a strong foothold in the bacterial conjunctivitis drugs market in the U.S.

The U.S. bacterial conjunctivitis drugs market is segmented as follows:

U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
Fluoroquinolones
Ciprofloxacin
Ofloxacin
Levofloxacin
Moxifloxacin
Gatifloxacin
Besifloxacin
Aminoglycosides
Tobramycin
Gentamycin
Macrolides
Erythromycin
Azithromycin
Others
U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
Vancomycin Ophthalmic Ointment
Early Stage (Phase I and Phase II trials) – Tabular Representation

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Infectious Disease Drugs: The Chinese Market

Infectious Disease Drugs: The Chinese Market

  • $ 6650
  • Industry report
  • March 2017
  • by BCC Research

Use this report to: - Assess market dynamics of Chinese market for both communicable and - non-communicable infectious disease drugs, their opportunities and restraints. - Evaluate Chinese drug market ...

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

  • $ 4995
  • Industry report
  • March 2017
  • by GBI Research

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market Summary Respiratory complications are a ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary Bacteria are a major class of prokaryotic ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • April 2017
    44 pages
  • Therapy  

    Serotonin Speci...  

    Antidepressant  

  • United States  

View report >

Anti-Infective Market in the Netherlands and Germany

  • April 2017
    10 pages
  • Anti-Infective  

  • Netherlands  

    Germany  

    Europe  

View report >

Anti-Infective Market in the UK

  • April 2017
    11 pages
  • Anti-Infective  

    Point Of Care T...  

    Hospital  

  • United Kingdom  

View report >

Anti-infective Market

26 days ago

Related Market Segments :

Anti-Infective
Eye Disease

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.